Drug Profile
Bazlitoran - Aceragen
Alternative Names: Bazlitoran-sodium; IMO-8400Latest Information Update: 20 Jan 2023
Price :
$50
*
At a glance
- Originator Idera Pharmaceuticals
- Developer Aceragen
- Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antisense oligonucleotides; Immunotherapies
- Mechanism of Action Toll-like receptor 7 antagonists; Toll-like receptor 8 antagonists; Toll-like receptor 9 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Suspended Diffuse large B cell lymphoma; Waldenstrom's macroglobulinaemia
- No development reported Graft-versus-host disease; Systemic lupus erythematosus
- Discontinued Dermatomyositis; Duchenne muscular dystrophy; Plaque psoriasis
Most Recent Events
- 17 Jan 2023 Idera Pharmaceuticals is now called Aceragen
- 15 Mar 2022 Idera Pharmaceuticals has chemical composition of matter patent protection for bazlitoran in US
- 08 Nov 2019 Efficacy and safety data from a phase II trial in Dermatomyositis presented at the 83rd American College of Rheumatology and the 54th Association of Rheumatology Health Professionals Annual Scientific Meeting (ACR/ARHP-2019)